Cargando…

Expression and regulatory network of E3 ubiquitin ligase NEDD4 family in cancers

NEDD4 family represent an important group of E3 ligases, which regulate various cellular pathways of cell proliferation, cell junction and inflammation. Emerging evidence suggested that NEDD4 family members participate in the initiation and development of tumor. In this study, we systematically inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Liangzi, Li, Hao, Liu, Xiaofang, Wang, Yubang, Zheng, Bowen, Xing, Chengzhong, Zhang, Naijin, Liu, Jingwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251597/
https://www.ncbi.nlm.nih.gov/pubmed/37291499
http://dx.doi.org/10.1186/s12885-023-11007-w
Descripción
Sumario:NEDD4 family represent an important group of E3 ligases, which regulate various cellular pathways of cell proliferation, cell junction and inflammation. Emerging evidence suggested that NEDD4 family members participate in the initiation and development of tumor. In this study, we systematically investigated the molecular alterations as well as the clinical relevance regarding NEDD4 family genes in 33 cancer types. Finally, we found that NEDD4 members showed increased expression in pancreas cancer and decreased expression in thyroid cancer. NEDD4 E3 ligase family genes had an average mutation frequency in the range of 0-32.1%, of which HECW1 and HECW2 demonstrated relatively high mutation rate. Breast cancer harbors large amount of NEDD4 copy number amplification. NEDD4 family members interacted proteins were enriched in various pathways including p53, Akt, apoptosis and autophagy, which were confirmed by further western blot and flow cytometric analysis in A549 and H1299 lung cancer cells. In addition, expression of NEDD4 family genes were associated with survival of cancer patients. Our findings provide novel insight into the effect of NEDD4 E3 ligase genes on cancer progression and treatment in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11007-w.